PIA
PVLA

Piedmont Investment Advisors’s Palvella Therapeutics PVLA Stock Holding History

Piedmont Investment Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11
Closed -$5K – 2343
2018
Q2 		$5K Buy
+11
New +$5.23K ﹤0.01% 2159

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piedmont Investment Advisors's PVLA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Palvella Therapeutics (PVLA) in Q3 2018, closing a stake of 11 shares — an estimated $5K sold.

Piedmont Investment Advisors first reported a position in PVLA in Q2 2018 and held it in 1 quarter. The position peaked at $5K in Q2 2018. 105 funds tracked by Wall St. Rank hold PVLA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Palvella Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 11 Palvella Therapeutics shares in Q3 2018, an estimated $5K.
  • Piedmont Investment Advisors first reported a position in Palvella Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Palvella Therapeutics position peaked at $5K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.